Key result
Olpasiran reduces atherogenic lipoproteins in secondary OCEAN(a)-DOSE trial analysis.
Why the study?
Does the small-interfering RNA olpasiran affect atherogenic lipoproteins?
Does the small-interfering RNA olpasiran affect atherogenic lipoproteins?
This secondary analysis of the OCEAN(a)-DOSE trial evaluates the impact of olpasiran on atherogenic lipoproteins.
This secondary analysis of the OCEAN(a)-DOSE randomized clinical trial investigates the effect of the small-interfering RNA olpasiran on atherogenic lipoproteins.
No takes yet. Share an insight, caveat, or question.
Zimerman et al. (2025) studied this question. Olpasiran, a small-interfering RNA, was investigated for its effects on atherogenic lipoproteins in a secondary analysis of the OCEAN(a)-DOSE randomized clinical trial.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: